EGFR-TKIs, as competitive inhibitors of adenosine triphosphate (ATP) in the TKIS domain of EGFR, inhibit abnormal proliferation and differentiation of tumor cells by inhibiting EGFR and blocking its downstream signal transduction, and ultimately inhibiting tumor growth and progression. The gene discussed is EGFR; the disease is neoplasm.